Drug Type Small molecule drug |
Synonyms NOV-1401 (National OncoVenture) + [4] |
Target |
Action inhibitors |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC23H23FN4O2 |
InChIKeyYNBQAYKYNYRCCA-UHFFFAOYSA-N |
CAS Registry1681017-83-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced gastric carcinoma | Phase 2 | China | 28 Jun 2021 | |
Advanced gastric carcinoma | Phase 2 | United States | 28 Jun 2021 | |
Advanced gastric carcinoma | Phase 2 | South Korea | 28 Jun 2021 | |
HRD positive cancer | Phase 2 | South Korea | 06 Nov 2019 | |
Breast Cancer | Discovery | South Korea | 16 Sep 2021 | |
Esophageal Carcinoma | Discovery | South Korea | 01 Jan 2021 | |
Esophageal Carcinoma | Discovery | China | 01 Jan 2021 | |
Esophageal Carcinoma | Discovery | United States | 01 Jan 2021 | |
Solid tumor | Discovery | South Korea | 06 Nov 2019 | |
Advanced Malignant Solid Neoplasm | Discovery | South Korea | 29 Aug 2017 |
Phase 1 | 32 | (xjyqjehshc) = Not observed up to 240 mg/d. maeumxooxa (unzxwucfqm ) View more | Positive | 01 Feb 2025 | |||
Phase 1 | Metastatic Gastric Carcinoma HRD gene mutations | 26 | Venadaparib plus irinotecan | (hysaqfhnrv) = lucfbzhdcn qmwmyuxelk (lkrqniljdg ) View more | Positive | 24 May 2024 | |
Placebo plus irinotecan | (jdvkhuvrum) = hkghyzguek hukcnyqfla (bipexhpdpx, 2.9 - 5.5) | ||||||
NCT04174716 (ASCO2023) Manual | Phase 1 | 8 | (ATMmASXL1m) | (xogeydyzlo) = khfgeqgozx ymuifudhif (vpkxwwpxgn ) View more | Positive | 31 May 2023 | |
(ATMmASXL1wt) | (xogeydyzlo) = xnozanmgzk ymuifudhif (vpkxwwpxgn ) View more | ||||||
Phase 1/2 | 14 | (pspdyvdgod) = 8/14 (57%) tkobqjsgkd (ruevgwwlfb ) View more | - | 16 Sep 2021 | |||
Phase 1 | 32 | (yewcveknpo) = Frequently observed adverse drug reactions were as follows – Anemia (56%), nausea (38%) and neutropenia (25%). ryvzwhfhus (zoqnxcdysk ) | Positive | 20 May 2021 | |||
(BRCAm(+)) |